“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Progressing towards the development of
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Agreement expands reach of physician-developed, industry-leading clinical training programs
San Francisco and Mumbai, July 11, 2017: The American Academy of Ophthalmology and Pharma major Lupin Limited (Lupin) today announced an agreement that would seek to expand and enhance continuing ophthalmic education in India. The effort is expected to reach 3,000 ophthalmologists in the country.
The collaboration will provide ophthalmologists access to several clinical education tools including the Academy’s flagship clinical education resource, the Ophthalmic News and Education® Network. The World’s largest online compendium of ophthalmic knowledge, the ONE Network is accessed by approximately 130,000 users every month.
The Academy typically offers access to the ONE Network and its other educational resources as a benefit of Academy membership as well as to ophthalmologists in other countries through a special application. The collaboration provides a new channel for distributing this content in India. The Academy also distributes its content in India to 16,000 members of the All India Ophthalmological Society. Through this partnership, over 3,000 ophthalmologists across the country will be provided online access to knowledge repository, which includes journals and videos to help practitioners stay abreast of the latest developments in the space.
Jane Aguirre, Vice President for membership and alliances for the American Academy of Ophthalmology, said “The Academy’s mission is to advance clinical education to ensure ophthalmologists deliver highest-quality eye care to their patients. This relationship with Lupin will help extend these valuable resources to more ophthalmologists in India.”
Rajeev Sibal, President, Indian Region Formulations, Lupin Limited, said “It gives me great pleasure to announce this collaborative program with the American Academy of Ophthalmology, which is a leading global authority in ophthalmic education. Lupin has always been at the forefront in disseminating the most sought and updated knowledge among Indian doctors in various fields through associations with many renowned academic institutions in the world. We are sure that this association will help quicken the pace with which ophthalmologists in India are able to obtain new clinical knowledge and training, thus bolstering the fight against preventable blindness in our country.”
About the American Academy of Ophthalmology
The American Academy of Ophthalmology is the world’s largest association of eye physicians and surgeons. A global community of 32,000 medical doctors, we protect sight and empower lives by setting the standards for ophthalmic education and advocating for our patients and the public. We innovate to advance our profession and to ensure the delivery of the highest-quality eye care. Our EyeSmart® program provides the public with the most trusted information about eye health. For more information, visit www.aao.org.
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 4th and the 6th largest generics pharmaceutical company by market capitalization and revenues globally (March 31st, 2017, Bloomberg). The Company is the 4th largest pharmaceutical player in the US by prescriptions (Quintiles IMS MAT March 2017); the 2nd largest Indian pharmaceutical company by global revenues; the 6th largest generic pharmaceutical player in Japan and the 6th largest company in Indian Pharmaceutical Market (Quintiles IMS MAT March 2017).
For the financial year ended 31st March, 2017, Lupin’s Consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinlimited
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.
For further information or queries please contact –
Head – Corporate Communications
Ph: +91-22-66402531 / 9811665000
American Academy of Ophthalmology
+ 1 (415) 561-8534